Most of the identified bioactive peptides were able to inhibit key enzymes involved in the progression of cardiovascular diseases (angiotensin-converting enzyme, ACE) and diabetes (di-peptidyl-peptidase-IV, DPP-IV). Here, ACE is linked to cardiovascular disorder.